MPL and autoimmune thrombocytopenic purpura: Altogether, Epimedium may exert therapeutic potential in mice with ITP by downregulating the expression of p-STAT3 in the JAK2/STAT3 signaling pathway, and regulating the TPO/MPL metabolic process in the bone marrow.